Journal
CANCER CAUSES & CONTROL
Volume 23, Issue 3, Pages 473-485Publisher
SPRINGER
DOI: 10.1007/s10552-012-9897-x
Keywords
Breast cancer; Obesity; Hormone receptor status; Abdominal adiposity; Hormone therapy
Funding
- National Cancer Institute [R01 CA77398, HHSN261 201000036C]
- California Breast Cancer Research Fund [97-10500]
- California Department of Health Services [103885]
- Cancer Prevention Institute of California [HHSN261201000035C]
- University of Southern California [HHSN261201000034C]
- Public Health Institute [1U58 DP000807-01]
Ask authors/readers for more resources
To evaluate how the association between body size and breast cancer risk varies by tumor receptor subtype, host factors, and other exposures among women in the California Teachers Study cohort. Among 52,642 postmenopausal women, 2,321 developed invasive breast cancer with known estrogen- and progesterone-receptor status (1,652 ER+PR+, 338 ER+PR-, and 312 ER-PR-) between 1995 and 2007. In a subset of 35,529 with waist circumference data, 1,377 developed invasive breast cancer with known ERPR status (991 ER+PR+, 208 ER+PR-, 169 ER-PR-) between 1997 and 2007. Multivariate Cox regression was performed to estimate relative risks (RR) and 95% confidence intervals (CI). Obesity, adult weight gain of a parts per thousand yen40 pounds, greater abdominal adiposity, and greater height increased the risk of ER+PR+ breast cancer. The increased risk associated with postmenopausal obesity was limited to those who did not use hormone therapy (HT) at cohort entry (RR = 1.37; 95% CI, 1.05-1.78 for BMI a parts per thousand yen 30 vs. < 25 kg/m(2); p-interaction = 0.14) and those who were not overweight or obese at age 18 (p-interaction = 0.06). The increased risk associated with greater abdominal adiposity was limited to those who were not also overweight or obese (p-interaction = 0.01). Neither obesity, abdominal adiposity, nor height was associated with the risk of ER-PR- tumors. The effects of body size on postmenopausal breast cancer risk differed by hormone receptor subtype, and among women with ER+PR+ tumors, by HT use and early adult body size.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available